Part 2 Consents
On 12/8/2011, the Commission required laboratory testing companies Laboratory Corporation of America Holdings (LabCorp) and Orchid Cellmark Inc. (Orchid) to divest a portion of Orchid's paternity testing business, to resolve the FTC complaint alleging that LabCorp's $85.4 million acquisition of Orchid would have an anticompetitive impact in the market for paternity testing services used by government agencies. The FTC's complaint alleges that LabCorp's acquisition of Orchid would illegally reduce competition in the U.S. market for paternity testing services provided to government agencies. Under the proposed settlement order, the portion of Orchid's U.S. paternity testing business that is focused on sales to government agencies, and related assets, will be sold to another testing company, DNA Diagnostics Center (DDC). On 2/1/2012, the FTC approved a final order settling charges concerning Laboratory Corporation of America Holdings' (LabCorp) proposed acquisition of rival firm Orchid Cellmark Inc.